Heterocyclic compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8912180
SERIAL NO

13762906

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3Kδ selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTELLAS PHARMA INCCHUO-KU TOKYO 103-8411

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Asano, Toru Tokyo, JP 43 715
Fukahori, Hidehiko Tokyo, JP 47 573
Imada, Sunao Tokyo, JP 9 154
Kato, Koji Tokyo, JP 221 2108
Kozuki, Yoshihiro Tokyo, JP 3 60
Maeda, Junko Tokyo, JP 7 33
Shiwaku, Masahiko Tokyo, JP 1 12
Takahashi, Fumie Tokyo, JP 13 194

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 16, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00